Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: Dual and selective SphK inhibitors from the University of Virginia

Article Snippet: These inhibitors demonstrate that engagement of the target is indexed by blood S1P levels. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 Dual and selective SphK inhibitors from the University of Virginia table ft1 table-wrap mode="anchored" t5 caption a7 Title application # applicant Pharmaceutical compounds as inhibitors of SphK WO 2012/069852 Almac Discovery Ltd. Imidamide SphK inhibitors WO 2011/020116 University of Virginia Long chain base SphK inhibitors WO 2013/119946 University of Virginia Selective inhibitors and allosteric activators of SphK WO 2014/118556 City Univ New York & Univ Strathclyde (UK) SphK inhibitor WO 2014/157382 Ajinomoto Benzene sulfonamide-based inhibitors of SphK WO 2016/007993 Univ South Australia Open in a separate window Pending Applications Claiming SphK inhibitors The increase in blood S1P accumulation in response to inhibition, or gene deletion, of one of its synthetic enzymes (i.e. SphK2) is curious and the underlying mechanism is unclear.

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: Pending Applications Claiming SphK inhibitors

Article Snippet: These inhibitors demonstrate that engagement of the target is indexed by blood S1P levels. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 Dual and selective SphK inhibitors from the University of Virginia table ft1 table-wrap mode="anchored" t5 caption a7 Title application # applicant Pharmaceutical compounds as inhibitors of SphK WO 2012/069852 Almac Discovery Ltd. Imidamide SphK inhibitors WO 2011/020116 University of Virginia Long chain base SphK inhibitors WO 2013/119946 University of Virginia Selective inhibitors and allosteric activators of SphK WO 2014/118556 City Univ New York & Univ Strathclyde (UK) SphK inhibitor WO 2014/157382 Ajinomoto Benzene sulfonamide-based inhibitors of SphK WO 2016/007993 Univ South Australia Open in a separate window Pending Applications Claiming SphK inhibitors The increase in blood S1P accumulation in response to inhibition, or gene deletion, of one of its synthetic enzymes (i.e. SphK2) is curious and the underlying mechanism is unclear.

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: SphK inhibitors from the City University of New York and University of Strathclyde (UK).

Article Snippet: These inhibitors demonstrate that engagement of the target is indexed by blood S1P levels. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 Dual and selective SphK inhibitors from the University of Virginia table ft1 table-wrap mode="anchored" t5 caption a7 Title application # applicant Pharmaceutical compounds as inhibitors of SphK WO 2012/069852 Almac Discovery Ltd. Imidamide SphK inhibitors WO 2011/020116 University of Virginia Long chain base SphK inhibitors WO 2013/119946 University of Virginia Selective inhibitors and allosteric activators of SphK WO 2014/118556 City Univ New York & Univ Strathclyde (UK) SphK inhibitor WO 2014/157382 Ajinomoto Benzene sulfonamide-based inhibitors of SphK WO 2016/007993 Univ South Australia Open in a separate window Pending Applications Claiming SphK inhibitors The increase in blood S1P accumulation in response to inhibition, or gene deletion, of one of its synthetic enzymes (i.e. SphK2) is curious and the underlying mechanism is unclear.

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: SphK inhibitors from Amgen and Virginia Commonwealth University

Article Snippet: These inhibitors demonstrate that engagement of the target is indexed by blood S1P levels. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window caption a7 Dual and selective SphK inhibitors from the University of Virginia table ft1 table-wrap mode="anchored" t5 caption a7 Title application # applicant Pharmaceutical compounds as inhibitors of SphK WO 2012/069852 Almac Discovery Ltd. Imidamide SphK inhibitors WO 2011/020116 University of Virginia Long chain base SphK inhibitors WO 2013/119946 University of Virginia Selective inhibitors and allosteric activators of SphK WO 2014/118556 City Univ New York & Univ Strathclyde (UK) SphK inhibitor WO 2014/157382 Ajinomoto Benzene sulfonamide-based inhibitors of SphK WO 2016/007993 Univ South Australia Open in a separate window Pending Applications Claiming SphK inhibitors The increase in blood S1P accumulation in response to inhibition, or gene deletion, of one of its synthetic enzymes (i.e. SphK2) is curious and the underlying mechanism is unclear.

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: Issued patents claiming SphK * inhibitors

Article Snippet: Inhibitors of SphK , 8,907,098 , Merck Patent GmBH.

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: Abandoned Applications Claiming SphK inhibitors

Article Snippet: Inhibitors of SphK , 8,907,098 , Merck Patent GmBH.

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: Dual and selective SphK inhibitors from the University of Virginia

Article Snippet: Inhibitors of SphK , 8,907,098 , Merck Patent GmBH.

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: Pending Applications Claiming SphK inhibitors

Article Snippet: Inhibitors of SphK , 8,907,098 , Merck Patent GmBH.

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: SphK inhibitors from the City University of New York and University of Strathclyde (UK).

Article Snippet: Inhibitors of SphK , 8,907,098 , Merck Patent GmBH.

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: SphK inhibitors from Amgen and Virginia Commonwealth University

Article Snippet: Inhibitors of SphK , 8,907,098 , Merck Patent GmBH.

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: Dual and selective SphK inhibitors from the University of Virginia

Article Snippet: Pharmaceutical compounds as inhibitors of SphK , WO 2012/069852 , Almac Discovery Ltd..

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: Pending Applications Claiming SphK inhibitors

Article Snippet: Pharmaceutical compounds as inhibitors of SphK , WO 2012/069852 , Almac Discovery Ltd..

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: SphK inhibitors from the City University of New York and University of Strathclyde (UK).

Article Snippet: Pharmaceutical compounds as inhibitors of SphK , WO 2012/069852 , Almac Discovery Ltd..

Techniques:

Journal: Expert opinion on therapeutic patents

Article Title: Sphingosine kinase inhibitors: a review of patent literature (2006–2015)

doi: 10.1080/13543776.2016.1226282

Figure Lengend Snippet: SphK inhibitors from Amgen and Virginia Commonwealth University

Article Snippet: Pharmaceutical compounds as inhibitors of SphK , WO 2012/069852 , Almac Discovery Ltd..

Techniques: